Approval · Notice of Compliance 35066 · 2025
FILRA: Notice of Compliance 35066
Issued March 24, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35066
- Date
- March 24, 2025
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Canadian reference product
- NEUPOGEN
Products in this notice
Medicinal ingredients
- FILGRASTIM (R-METHUG-CSF) 480 MCG per 0.8ML
- FILGRASTIM (R-METHUG-CSF) 300 MCG per 0.5ML